Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Wegener’s granulomatosis, now officially called **Granulomatosis with Polyangiitis (GPA)**, is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis) and the formation of granulomas—clusters of inflammatory cells—in the respiratory tract and kidneys. The disease can affect virtually any organ, but the classic triad involves the **upper airway (nose/sinuses), lower airway (lungs), and kidneys**.

• Incidence: Approximately 3 – 4 new cases per million people each year in the United States and Europe.¹
• Prevalence: Roughly 20 – 30 cases per million population.²
• Age: Most commonly diagnosed between ages 40‑65, but children and older adults can be affected.
• Gender: Slight male predominance (≈55 % male).
• Ethnicity: Higher rates reported in people of Northern European descent; lower rates in Asian populations, though the disease occurs worldwide.

Symptoms

Symptoms vary depending on which organs are involved and may develop rapidly (over weeks) or gradually (over months). Below is a comprehensive list, grouped by organ system.

Upper Respiratory Tract

• Chronic sinusitis – facial pain, pressure, nasal congestion that does not improve with typical treatments.
• Nasal crusting or ulceration – may cause nosebleeds (epistaxis).
• Otitis media – persistent ear infections or hearing loss.
• Ear pain or fullness – due to eustachian tube dysfunction.

Lower Respiratory Tract

• Cough – usually dry, can become productive if there is alveolar hemorrhage.
• Shortness of breath – especially on exertion.
• Chest pain – pleuritic or due to lung nodules.
• Hemoptysis – coughing up blood, a red‑flag symptom.
• Lung nodules or cavities – seen on imaging, may cause wheezing.

Renal (Kidney) Involvement

• Hematuria – red or brown urine from glomerulonephritis.
• Proteinuria – foamy urine indicating kidney damage.
• Decreased urine output – may progress to acute kidney injury.

General/Systemic

• Fever – low‑grade or high, often the first clue.
• Fatigue / malaise – profound tiredness unrelated to activity.
• Weight loss – unexplained, sometimes >10 % of body weight.
• Arthralgia – joint pain without swelling.
• Skin lesions – palpable purpura, ulcers, or nodules.
• Neuropathy – tingling, numbness, or mononeuritis multiplex.

Rare/Other Organ Involvement

• Eye inflammation (scleritis, uveitis)
• Cardiac involvement (pericarditis, conduction abnormalities)
• Gastrointestinal bleeding
• Hearing loss due to middle ear disease

Causes and Risk Factors

GPA is an **autoimmune vasculitis**; the exact trigger is unknown, but research points to a combination of genetic predisposition and environmental factors.

Immunologic Mechanism

• Autoantibodies called **c‑ANCA (cytoplasmic anti‑neutrophil cytoplasmic antibodies)**, which target proteinase‑3 (PR3) in neutrophils, are present in 80‑90 % of active cases.³
• These antibodies activate neutrophils, causing them to adhere to vessel walls and release inflammatory enzymes, leading to necrotizing vasculitis and granuloma formation.

Genetic Factors

• Specific HLA‑DQ alleles (e.g., HLA‑DQβ1*04) increase susceptibility.
• Polymorphisms in the **PR3** gene and **PTPN22** have been linked to higher risk.

Environmental Triggers

• Silica dust exposure (found in mining, construction) – epidemiologic studies show a 2‑3‑fold increased risk.⁴
• Chronic nasal carriage of *Staphylococcus aureus* – associated with higher relapse rates.
• Certain drugs (e.g., propylthiouracil, hydralazine) can induce ANCA‑associated vasculitis, although this drug‑induced form may differ clinically.

Who Is at Higher Risk?

• Adults aged 40‑65, especially males.
• Individuals with a family history of autoimmune disease.
• Occupational exposure to silica or other inhaled irritants.
• Patients with chronic nasal carriage of *S. aureus*.

Diagnosis

Because symptoms overlap with infections, malignancies, and other vasculitides, a systematic approach is essential.

Clinical Evaluation

• Detailed history (symptom chronology, occupational exposure, drug use).
• Comprehensive physical exam focusing on ENT, pulmonary, renal, skin, and neurologic findings.

Laboratory Tests

• ANCA testing – c‑ANCA (anti‑PR3) positive in 80‑90 % of active GPA; p‑ANCA (anti‑MPO) may be seen in a minority.⁵
• Complete blood count (CBC) – anemia, leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria, proteinuria.
• Inflammatory markers – ESR, CRP (usually elevated).
• Serology for infectious mimics (e.g., TB, hepatitis B/C).

Imaging Studies

• Chest X‑ray – nodules, cavitations, infiltrates.
• High‑resolution CT (HRCT) of chest – more sensitive for pulmonary lesions.
• Sinus CT – mucosal thickening, bony destruction.
• Optional: MRI of brain or orbit if neurologic/ocular symptoms present.

Biopsy (Gold Standard)

• Obtaining tissue from an affected site (nasal mucosa, lung nodule, or kidney) confirms necrotizing granulomatous inflammation with vasculitis.⁶
• Kidney biopsy is critical when rapidly progressive glomerulonephritis is suspected.

Classification Criteria

The 2022 ACR/EULAR GPA classification criteria require a combination of clinical features, ANCA status, and biopsy findings; a score ≥ 5 points confirms GPA.⁷

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing side effects. Treatment is usually coordinated by a rheumatologist and may involve pulmonology, nephrology, and ENT specialists.

Induction Therapy (to achieve remission)

• High‑dose glucocorticoids – e.g., prednisone 1 mg/kg/day (often 40‑60 mg) tapered over 4‑6 months.
• Immunosuppressive agents (choose one):
  • Rituximab 375 mg/m² weekly for 4 weeks or 1 g IV on days 0 and 14 – preferred for patients with severe renal disease or relapsing disease (based on the RAVE trial).⁸
  • Cyclophosphamide** (IV pulse 15 mg/kg every 2‑3 weeks or oral 2 mg/kg/day) – effective but carries risk of infertility, bladder toxicity, and infections.
• For life‑threatening organ involvement (e.g., diffuse alveolar hemorrhage, rapidly progressive glomerulonephritis), combine **plasmapheresis** with steroids and cyclophosphamide or rituximab (based on the PEXIVAS trial—considered in select cases).⁹

Maintenance Therapy (to prevent relapse)

• Azathioprine** 2‑2.5 mg/kg/day or Mycophenolate Mofetil** 1‑1.5 g twice daily.
• Low‑dose glucocorticoids (≤10 mg prednisone daily) for the first 12‑18 months, then taper.
• Rituximab can also be used for maintenance (500 mg IV every 6 months for 2‑4 years).

Adjunctive Care

• Prophylaxis against opportunistic infections: trimethoprim‑sulfamethoxazole (for *Pneumocystis jirovecii* pneumonia) and vaccinations (influenza, pneumococcal, COVID‑19).
• Bone protection: calcium + vitamin D and bisphosphonates if steroids >3 months.
• Fertility counseling – consider sperm banking or gonadotropin‑releasing hormone agonists before cyclophosphamide.
• Regular monitoring: CBC, renal function, ANCA titers, and imaging every 3‑6 months during the first year.

Living with Wegener’s Granulomatosis

Long‑term management focuses on symptom control, medication adherence, and quality of life.

Daily Management Tips

• Medication schedule – use a pill organizer or smartphone reminders.
• Hydration – essential for kidney health; aim for 2–3 L/day unless otherwise directed.
• Protect your nose – saline sprays or humidifiers relieve crusting; avoid nasal picking.
• Exercise – low‑impact activities (walking, swimming) improve stamina and bone health.
• Sun protection – some immunosuppressants increase photosensitivity.
• Monitor symptoms – keep a journal of cough, urine changes, fevers, or new skin lesions.
• Vaccinations – keep immunizations up to date but avoid live vaccines while on high‑dose immunosuppression.
• Support networks – connect with patient groups (e.g., Vasculitis Foundation) for emotional support.

Follow‑up Care

Typical schedule for stable disease:

• Every 1–2 months during induction.
• Every 3–4 months for the first year of maintenance.
• Every 6–12 months thereafter, or sooner if symptoms recur.

Prevention

Because GPA’s exact cause is unclear, true primary prevention is not possible. However, risk reduction strategies include:

• Minimizing exposure to silica dust (use protective masks, ventilation).
• Prompt treatment of chronic sinus infections; consider eradication of *S. aureus* nasal carriage with mupirocin if recurrent.
• Avoiding drugs known to trigger ANCA vasculitis (e.g., propylthiouracil) unless medically necessary.
• Maintaining a healthy immune system through balanced diet, regular exercise, and adequate sleep.

Complications

If left untreated or poorly controlled, GPA can lead to serious, potentially irreversible damage.

• Renal failure – up to 50 % of patients develop chronic kidney disease; dialysis or transplant may be required.
• Respiratory failure – due to diffuse alveolar hemorrhage or extensive pulmonary fibrosis.
• Permanent sinus or facial bone destruction – can cause chronic sinusitis, facial deformity.
• Peripheral neuropathy – mononeuritis multiplex causing disability.
• Skin scarring – from ulcerations or necrotic lesions.
• Secondary infections – opportunistic infections from immunosuppression.
• Increased malignancy risk – especially bladder cancer with cyclophosphamide exposure.
• Relapse – up to 30‑50 % experience at least one relapse; early detection is essential.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe shortness of breath or chest pain.
• Visible coughing up large amounts of blood (hemoptysis).
• Rapidly increasing swelling of the face or lips (possible airway obstruction from nasal/oral ulceration).
• Gross blood in the urine or a sudden decline in urine output.
• High fever (>101 °F / 38.5 °C) with chills and worsening pain.
• Sudden loss of vision, double vision, or severe eye pain.
• Sudden weakness, numbness, or facial droop suggestive of stroke.
• Severe abdominal pain with vomiting (possible GI bleeding).

These signs may indicate life‑threatening organ involvement that requires immediate medical intervention.

---

**References**

1. Centers for Disease Control and Prevention. “Vasculitis – Epidemiology.” https://www.cdc.gov (accessed May 2024).
2. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” https://www.mayoclinic.org (2023).
3. Jennette JC, et al. “ANCA‑associated vasculitis.” *New England Journal of Medicine*. 2020;382: 238–250.
4. Cleveland Clinic. “Silica exposure and vasculitis risk.” https://my.clevelandclinic.org (2022).
5. Mayo Clinic. “ANCA testing and interpretation.” (2024).
6. Hogan SL, et al. “Pathology of granulomatosis with polyangiitis.” *Histopathology*. 2021;78: 64‑77.
7. American College of Rheumatology/European League Against Rheumatism. “2022 Classification Criteria for GPA.” *Arthritis & Rheumatology*. 2022.
8. Stone JH, et al. “Rituximab versus cyclophosphamide for ANCA‑associated vasculitis.” *NEJM*. 2010;363: 221–232.
9. Walsh M, et al. “Plasma exchange in severe ANCA‑associated vasculitis (PEXIVAS).” *NEJM*. 2020;382: 1303‑1314.